102 related articles for article (PubMed ID: 8823310)
21. Blood progenitor cell (BPC) mobilization studied in multiple myeloma, solid tumor and non-Hodgkin's lymphoma patients after combination chemotherapy and G-CSF.
Engelhardt M; Winkler J; Waller C; Lange W; Mertelsmann R; Henschler R
Bone Marrow Transplant; 1997 Mar; 19(6):529-37. PubMed ID: 9181898
[TBL] [Abstract][Full Text] [Related]
22. A Phase I trial of 90Y-anti-carcinoembryonic antigen chimeric T84.66 radioimmunotherapy with 5-fluorouracil in patients with metastatic colorectal cancer.
Wong JY; Shibata S; Williams LE; Kwok CS; Liu A; Chu DZ; Yamauchi DM; Wilczynski S; Ikle DN; Wu AM; Yazaki PJ; Shively JE; Doroshow JH; Raubitschek AA
Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5842-52. PubMed ID: 14676105
[TBL] [Abstract][Full Text] [Related]
23. The addition of interferon or high dose cyclophosphamide to standard chemotherapy in the treatment of patients with multiple myeloma: phase III Eastern Cooperative Oncology Group Clinical Trial EST 9486.
Oken MM; Leong T; Lenhard RE; Greipp PR; Kay NE; Van Ness B; Keimowitz RM; Kyle RA
Cancer; 1999 Sep; 86(6):957-68. PubMed ID: 10491521
[TBL] [Abstract][Full Text] [Related]
24. High rates of long-lasting remissions after 5-day bendamustine chemotherapy cycles in pre-treated low-grade non-Hodgkin's-lymphomas.
Bremer K
J Cancer Res Clin Oncol; 2002 Nov; 128(11):603-9. PubMed ID: 12458340
[TBL] [Abstract][Full Text] [Related]
25. Reinfusion of unprocessed, granulocyte colony-stimulating factor-stimulated whole blood allows dose escalation of 186Relabeled chimeric monoclonal antibody U36 radioimmunotherapy in a phase I dose escalation study.
Colnot DR; Ossenkoppele GJ; Roos JC; Quak JJ; de Bree R; Börjesson PK; Huijgens PC; Snow GB; van Dongen GA
Clin Cancer Res; 2002 Nov; 8(11):3401-6. PubMed ID: 12429627
[TBL] [Abstract][Full Text] [Related]
26. Therapeutic potential of humanized anti-interleukin-6 receptor antibody: antitumor activity in xenograft model of multiple myeloma.
Tsunenari T; Akamatsu K; Kaiho S; Sato K; Tsuchiya M; Koishihara Y; Kishimoto T; Ohsugi Y
Anticancer Res; 1996; 16(5A):2537-44. PubMed ID: 8917348
[TBL] [Abstract][Full Text] [Related]
27. Measurement of whole body interleukin-6 (IL-6) production: prediction of the efficacy of anti-IL-6 treatments.
Lu ZY; Brailly H; Wijdenes J; Bataille R; Rossi JF; Klein B
Blood; 1995 Oct; 86(8):3123-31. PubMed ID: 7579407
[TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetics of interleukin-6 during therapy with anti-interleukin-6 monoclonal antibodies: enhanced clearance of interleukin-6 by a combination of three anti-interleukin-6 antibodies.
Montero-Julian FA; Gautherot E; Wijdenes J; Klein B; Brailly H
J Interferon Res; 1994 Oct; 14(5):301-2. PubMed ID: 7861038
[No Abstract] [Full Text] [Related]
29. Overall interleukin-6 production exceeds 7 mg/day in multiple myeloma complicated by sepsis.
Lu ZY; Brailly H; Rossi JF; Wijdenes J; Bataille R; Klein B
Cytokine; 1993 Nov; 5(6):578-82. PubMed ID: 8186369
[TBL] [Abstract][Full Text] [Related]
30. Inhibiting IL-6 in human multiple myeloma.
Klein B; Lu ZY; Gaillard JP; Harousseau JL; Bataille R
Curr Top Microbiol Immunol; 1992; 182():237-44. PubMed ID: 1490360
[No Abstract] [Full Text] [Related]
31. Clinical applications of IL6 inhibitors.
Klein B; Lu ZY; Bataille R
Res Immunol; 1992 Sep; 143(7):774-6. PubMed ID: 1439155
[No Abstract] [Full Text] [Related]
32. [Anti-cytokine therapy for intractable hematologic diseases using monoclonal antibodies].
Nishimoto N
Nihon Naika Gakkai Zasshi; 2004 Feb; 93(2):390-6. PubMed ID: 15007951
[No Abstract] [Full Text] [Related]
33. Combination therapy of anti-CD4 and anti-IL6 monoclonal antibodies in a case of severe spondylarthropathy.
Wendling D; Racadot E; Toussirot E; Wijdenes J
Br J Rheumatol; 1996 Dec; 35(12):1330. PubMed ID: 9010072
[No Abstract] [Full Text] [Related]
34. In vitro and in vivo antitumor effects of the recombinant immunotoxin IL6(T23)-PE38KDEL in multiple myeloma.
Guo DJ; Han JS; Li YS; Liu ZS; Lu SY; Ren HL
Oncol Lett; 2012 Aug; 4(2):311-318. PubMed ID: 22844376
[TBL] [Abstract][Full Text] [Related]
35. RAPID PRODUCTION OF ANTI-M PROTEIN ANTIBODIES.
Markowitz AS
J Bacteriol; 1963 Feb; 85(2):495-6. PubMed ID: 16561997
[No Abstract] [Full Text] [Related]
36. Regulation of endogenous cortin production.
HEMPHILL RE; REISS M
Endocrinology; 1947 Jul; 41(1):17-20. PubMed ID: 20259229
[No Abstract] [Full Text] [Related]
37. Blocking interleukin-6 activity with chimeric anti-IL6 monoclonal antibodies in multiple myeloma: effects on soluble IL6 receptor and soluble gp130.
Van Zaanen HC; Lokhorst HM; Aarden LA; Rensink HJ; Warnaar SO; Van Oers MH
Leuk Lymphoma; 1998 Nov; 31(5-6):551-8. PubMed ID: 9922045
[TBL] [Abstract][Full Text] [Related]
38. Interleukin-6 at the Host-Tumor Interface: STAT3 in Biomolecular Condensates in Cancer Cells.
Sehgal PB
Cells; 2022 Mar; 11(7):. PubMed ID: 35406728
[TBL] [Abstract][Full Text] [Related]
39. Immunotherapy of multiple myeloma.
Minnie SA; Hill GR
J Clin Invest; 2020 Apr; 130(4):1565-1575. PubMed ID: 32149732
[TBL] [Abstract][Full Text] [Related]
40. Interleukin-6: designing specific therapeutics for a complex cytokine.
Garbers C; Heink S; Korn T; Rose-John S
Nat Rev Drug Discov; 2018 Jun; 17(6):395-412. PubMed ID: 29725131
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]